GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsDownload Poster_Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial.Download Poster_BAT8008, ...
Guangzhou and London – May 22, 2025) Injection, a biosimilarreferencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera’s third FDA approved product. “The approval of STARJEMZA® is another significantaccomplishment for Bio-Thera, establishi...
Guangzhou, China– April 14, 2025 –Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, will have anoral presentation in collaboration with medical centers at ...
